• 1
    Swerdlow SH, Campo E, Seto M, et al. Mantle cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008:229232.
  • 2
    Majlis A, Pugh WC, Rodriguez MA, et al. Mantle cell lymphoma: correlation of clinical outcome and biologic features with 3 histologic variants. J Clin Oncol. 1997;15:16641671.
  • 3
    Romaguera JE, Fayad LE, Feng L, et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol. 2010;150:200208.
  • 4
    Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558565.
  • 5
    Tam CS, Bassett R, Ledesma C, et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood. 2009;113:41444152.
  • 6
    Budde LE, Guthrie KA, Till BG, et al. Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. J Clin Oncol. 2011;29:30233029.
  • 7
    Geisler CH, Kolstad A, Laurell A, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+ autologous stem-cell support: still very long survival but late relapse do occur. Br J Haematol. 2012;158:355362.
  • 8
    Todorovic M, Balint B, Andjelic B, et al. Outcome prediction of advanced mantle cell lymphoma by international prognostic index versus different mantle cell lymphoma indexes: one institution study. Med Oncol. 2012;29:22122219.
  • 9
    Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3:185197.
  • 10
    Garcia M, Romaguera JE, Inamdar KV, et al. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine. Cancer. 2009;115:10411048.
  • 11
    Fernandez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010;70:14081418.
  • 12
    Ondrejka SL, Lai R, Smith SD, et al. Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica. 2011;96:11211127.
  • 13
    Gressin R, Caulet-Maugendre S, Deconinck E, et al; French GOELAMS Group. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. Haematologica. 2010;95:13501357.
  • 14
    Caraway NP, Gu J, Lin P, Romaguera JE, Glassman A, Katz R. The utility of interphase fluorescence in situ hybridization for the detection of the translocation t(11;14)(q13;q32) in the diagnosis of mantle cell lymphoma on fine-needle aspiration specimens. Cancer. 2005;105:110118.
  • 15
    Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:12441253.
  • 16
    Cheson BD, Pfistner B, Juweid ME, et al. International harmonization project on lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579586.
  • 17
    Luthra R, Sarris AH, Hai S, et al. Real-time 5′->3′ exonuclease-based PCR assay for detection of the t(11;14)(q13;q32). Am J Clin Pathol. 1999;112:524530.
  • 18
    Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457481.
  • 19
    Kalbfleish JD, Prentice RL. Relative Risk (Cox) Regression Models. In: The Statistical Analysis of Failure Time Data. Hoboken, NJ: John Wiley & Sons Inc; 2002; pp. 95142.
  • 20
    O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:21652170.
  • 21
    Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001;19:21532164.
  • 22
    Piro LT, White CA, Grillo-Lopez AJ, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1999;10:655661.
  • 23
    Zipp L, Saliba RM, Valverde R, et al. Mature results of BEAM/high-dose rituximab vs BEAM/yttrium-90 ibritumomab tiuxetan (Zevalin) and autologous stem cell transplantation (ASCT) for relapsed CD20+ follicular and diffuse large b-cell lymphoma: survival outcomes and risk of secondary malignancies [abstract]. Blood. 2011;118:2005.
  • 24
    Martin P, Chadburn A, Christos P, at al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27:12091213.
  • 25
    Nygren L, Baumgartner Wennerholm S, Klimkowska M, Christensson B, Kimby E, Sander B. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood. 2012;119:42154213.
  • 26
    Schaffel R, Hedvat CV, Teruya-Feldstein J, et al. Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Ann Oncol. 2010;21:133139.
  • 27
    Delarue R, Haioun C, Ribrag V, et al; Groupe d'Etude des Lymphomes de l'Adulte (GELA). CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood. 2013;121:4853.